ELI-002 2P is an innovative “off-the-shelf” therapeutic vaccine targeting KRAS mutations, which drive approximately 90% of pancreatic cancers and 50% of colorectal cancers . Unlike personalized mRNA vaccines, this standardized approach delivers synthesized peptides directly to lymph nodes to train T-cells to recognize and attack KRAS-mutated cancer cells.
Key Clinical Results: The Phase 1 AMPLIFY-201 trial in 25 patients (20 pancreatic, 5 colorectal) with minimal residual disease after surgery showed impressive outcomes. 68% of patients (17 of 25) developed robust T-cell responses, which correlated with improved survival. Updated data show a median recurrence-free survival of 16.3 months and median overall survival of 28.9 months.
Safety and Mechanism: The vaccine was well-tolerated and successfully trained the immune system to recognize cancer-driving mutations. It activates both helper (CD4+) and killer (CD8+) T-cells crucial for fighting cancer.
Future Outlook: The FDA has supported a registrational strategy for ELI-002, and a randomized Phase 2 trial is underway with results expected in the first half of 2025. The next-generation vaccine targets additional KRAS mutations to benefit more patients, and researchers are exploring combination therapies with immunotherapy drugs.
This represents a significant breakthrough in targeting the historically “undruggable” KRAS protein through immunotherapy rather than traditional small-molecule approaches.